Quanterix Corp (QTRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Instrument ...

GuruFocus.com11-13

Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Quanterix Corp (NASDAQ:QTRX) reported its sixth ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483261290?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BkRjiG8kOKTbtjfnqHD7sQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ff88425cf7b5f01a66afddacaa64d8f7","is_english":true,"pubTime":"2024-11-13 15:18","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483261290","market":"us","top_or_hot":-1,"title":"Quanterix Corp (QTRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Instrument ...","media":"GuruFocus.com","content":"<div>\n<p>Release Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nQuanterix Corp (NASDAQ:QTRX) reported its sixth ...</p>\n\n<a href=\"https://finance.yahoo.com/news/quanterix-corp-qtrx-q3-2024-071816254.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quanterix Corp (QTRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Instrument ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuanterix Corp (QTRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Instrument ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/quanterix-corp-qtrx-q3-2024-071816254.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Release Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nQuanterix Corp (NASDAQ:QTRX) reported its sixth ...</p>\n\n<a href=\"https://finance.yahoo.com/news/quanterix-corp-qtrx-q3-2024-071816254.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QTRX","symbol_name":"Quanterix Corp","start_time":0,"source_url":"https://finance.yahoo.com/news/quanterix-corp-qtrx-q3-2024-071816254.html","article_id":"2483261290","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BkRjiG8kOKTbtjfnqHD7sQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ff88425cf7b5f01a66afddacaa64d8f7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483261290","pubTimestamp":1731482296,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Quanterix Corp  reported its sixth consecutive quarter of double-digit revenue growth, with a 13% increase in Q3 2024.The company achieved a 36% growth in its Accelerator lab and an 8% growth in its consumables business.The company launched 16 new products year-to-date, including novel multiplexes, with plans to launch four more by the end of the year.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"QTRX":"Quanterix Corp"},"translate_title":"Quanterix Corp(QTRX)2024年第三季度收益看涨期权亮点：仪器收入强劲增长……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTRX":1},"content_text":"Release Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nQuanterix Corp (NASDAQ:QTRX) reported its sixth consecutive quarter of double-digit revenue growth, with a 13% increase in Q3 2024.\nThe company achieved a 36% growth in its Accelerator lab and an 8% growth in its consumables business.\nQuanterix Corp (NASDAQ:QTRX) has a strong balance sheet with nearly $300 million in liquidity and reduced cash usage to $3 million in the quarter.\nThe company launched 16 new products year-to-date, including novel multiplexes, with plans to launch four more by the end of the year.\nQuanterix Corp (NASDAQ:QTRX) is making significant progress in Alzheimer's disease testing, launching a multimarker assay as a lab-developed test with strong demand from clinicians.\n\n Negative Points \n\nQuanterix Corp (NASDAQ:QTRX) is facing challenges with its instrument revenue, which decreased by 39% in the quarter.\nThe company is undergoing a restatement of certain prior period financial statements, which may take longer to complete than expected.\nRevenue from the Asia Pacific region was down 34% in the period.\nThe company reported that revenue from lucent patient testing was immaterial for the quarter.\nThere is uncertainty around the reimbursement rates for single marker tests, which could impact future revenue from diagnostics.\n\n Q & A Highlights \n\nWarning! GuruFocus has detected 2 Warning Signs with QTRX.\n\nQ: How would you characterize the sales in the quarter for the Accelerator Lab in terms of new versus existing customers? A: (CEO) About 70 to 80% of the sales were from recurring customers. The Accelerator Lab continues to outperform, growing 36% this quarter and making up about 30% of our business. Our strategy of combining consumables and Accelerator services has resulted in 80% recurring revenues, showcasing a unique position of strength in the market.\nQ: Could you give us a sense of how diagnostics might contribute to your overall top-line growth next year? A: (CEO) The contribution from diagnostics will depend on patient utilization of therapies like Lambi and Kuma. We are focused on improving accessibility and reducing costs with blood-based markers, which should help more people access therapies. We will provide more guidance on this at the beginning of 2025.\nQ: Can you explain the difference between the multimarker panel and the single marker assay, and how they fit into future diagnostic use? A: (CEO) The multimarker panel, Lucent AD Complete, includes five markers and an algorithm to provide a more definitive result, reducing the intermediate zone by threefold compared to single marker tests. This makes it more effective for diagnosing Alzheimer's. The Bty Tau assay, launched recently, is expected to be important for staging tau pathology and monitoring patients in clinical trials, with potential future diagnostic applications.\nQ: How do you see the interplay between instrument and Accelerator revenue evolving given current macro dynamics? A: (CFO) There is a toggle between instrument and Accelerator revenue. While instrument sales have been challenging, the Accelerator has more than offset this decline, benefiting from strong demand in research and trials. We expect Accelerator to continue growing double digits even when instrument sales recover.\nQ: What are the next steps for reimbursement of the Lucent AD Complete test, and how do you plan to scale its commercialization? A: (CEO) We are focused on clinical utility studies and ongoing trials to support reimbursement submissions in 2025. We expect a higher reimbursement rate for the multimarker test compared to single markers. Our strategy involves both direct sales and partnerships to build global testing infrastructure, ensuring broad access to the test.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483261290"}